Literature DB >> 6128286

Somatostatin suppression of canine fasting bile secretion.

J B Hanks, W J Kortz, D K Andersen, R S Jones.   

Abstract

Somatostatin, a peptide present in hypothalamus, gastric mucosa, and pancreas, suppresses several gastrointestinal functions. We evaluated the effect of graded doses of intravenous somatostatin on taurocholate-stimulated bile flow awake fasting dogs. Somatostatin doses of 1.5-200 ng . kg-1 . min-1 significantly suppressed fasting biliary flow. Biliary lipid concentration showed progressive elevations approaching 200% with 200 ng . kg-1 . min-1 somatostatin, while lipid outputs were not altered. The data suggest that somatostatin inhibited bile salt-independent canalicular or ductular secretion, because bile flow, chloride, and bicarbonate output, and the biliary clearance of erythritol were significantly reduced, while bile salt output remained unchanged. In addition, suppression of basal insulin concentration occurred at somatostatin infusion of 200 ng . kg-1 . min-1. Additional studies in anesthetized dogs demonstrated that somatostatin could suppress bile secretion without altering hepatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6128286

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

Review 1.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

2.  Cholescintigraphic study of effect of somatostatin analog, octreotide, on bile secretion and gallbladder emptying in normal subjects.

Authors:  C Grimaldi; J Darcourt; A G Harris; E Lebot; F Lapalus; J Delmont
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

3.  Effect of somatostatin analog octreotide on human sphincter of Oddi.

Authors:  K F Binmoeller; R Dumas; A G Harris; J P Delmont
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

4.  Hepatic bile formation in the rat. Addition of vasoactive intestinal peptide to the equation.

Authors:  R G Knodell; N M Steele; L N Stanley
Journal:  Dig Dis Sci       Date:  1987-11       Impact factor: 3.199

5.  Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.

Authors:  S M Catnach; J V Anderson; P D Fairclough; R C Trembath; P A Wilson; E Parker; G M Besser; J A Wass
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

6.  Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.

Authors:  M F Stolk; K J van Erpecum; H P Koppeschaar; W I de Bruin; J B Jansen; C B Lamers; G P van Berge Henegouwen
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

Review 7.  The effect of drugs on bile flow and composition. An overview.

Authors:  L Okolicsanyi; F Lirussi; M Strazzabosco; R M Jemmolo; R Orlando; G Nassuato; M Muraca; G Crepaldi
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.